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Abstract
Background: Insight regarding transfusion practices in Hematopoietic Stem cell Transplantation (HSCT) are lacking
and the impact of red cell transfusion in this high risk group on outcomes following HSCT are not well
appreciated. Red blood cell transfusion can be life-saving, however, liberal use of transfusion in critically ill patients
failed to demonstrate significant clinical benefit. A large number of other observational studies have also
demonstrated an association between red blood cell transfusions and increased morbidity such as infections and
multi organ failure as well as increased mortality. The role of red cell transfusion on the clinical outcomes observed
in patients undergoing HSCT remains poorly understood and a prospective randomized study of transfusion is
required to gain insight and knowledge on best transfusion practices in this high risk population.
Methods: This report describes the design and methodological issues of a randomized pilot study evaluating red
cell transfusion triggers in the setting of Hematopoietic Stem Cell Transplantation. This study has been funded by a
peer review grant from the Canadian Blood Services and is registered on Clinicaltrials.gov NCT01237639.
Results: In 3 Canadian centres, 100 patients undergoing Hematopoietic Stem Cell Transplantation will be
randomized to either a restrictive (target hemoglobin of 70-90 g/L) or liberal (target hemoglobin of 90-110 g/L) red
cell transfusion strategy, based daily hemoglobin values up to 100 days post-transplant. The study will stratify
participants by centre and type of transplant. The primary goal is to demonstrate study feasibility and we will
collect clinical outcomes on 1) Transfusion Requirements, 2) Transplant Related Mortality, 3) Maximum grade of
acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Serious Infections, 6) Bearman Toxicity Score, 7)
Bleeding, 8) Quality of Life, 9) Number of Hospitalizations and 10) Number of Intensive Care Unit (ICU) Admissions.
Conclusion: Upon completion, this pilot trial will provide preliminary insight into red cell transfusion practice and
its influence in hematopoietic stem cell transplant outcomes. The results of this trial will inform the conduct of a
larger study.
Keywords: Hematopoietic Stem Cell Transplant, Red cell transfusion, Erythrocyte, Triggers, Randomized Clinical
Trial, Pilot
1. Background
Evidence based transfusion practices in Hematopoietic
Stem cell Transplantation (HSCT) are lacking and the
impact of red cell transfusion on outcomes following
HSCT are not well appreciated. Although, red blood cell
transfusion can be life-saving, liberal use of transfusion
in critically ill patients failed to demonstrate significant
clinical benefit in a landmark Canadian study [1]. In
fact, increased 30 day mortality was observed in a subset
of patients transfused at a higher hemoglobin level and
red blood cell transfusion may contribute to impaired
wound healing in various other settings. In one single-
centered retrospective study, patients undergoing allo-
geneic transplantation who had reduced hemoglobin at
the time of transplant received a greater number of red
cell transfusions and had increased transplant-related
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any medium, provided the original work is properly cited.mortality [2]. Similar results were obtained in a multi-
centered study coordinated by one of the authors [3]
and reduced hemoglobin prior to autologous transplan-
tation is associated with greater number of transfused
red cell units and increased toxicity [4]. Moreover, a
recent study suggests that red cell transfusion in cancer
patients is associated with increased risk of thrombosis
and in-hospital mortality [5]. Our systematic search of
the literature on transfusion strategies in HSCT reveals
a paucity of knowledge, in particular an absence of defi-
nitive clinical studies.
The most compelling evidence that red cell transfu-
sion may be harmful is derived from the TRICC study
[1]. In 838 critically ill patients randomized to a restric-
tive transfusion strategy (target hemoglobin of 70-90 g/L
with a hemoglobin transfusion threshold of 70 g/L), or a
liberal transfusion strategy (target hemoglobin of 100-
120 g/L with a hemoglobin transfusion threshold of 100
g/L), patients in the restrictive arm had lower hemoglo-
bin levels (received fewer red cell transfusions, and had
lower mortality at 30 days). The results from this semi-
nal trial demonstrated that a restrictive red blood cell
transfusion strategy reduces red cell transfusion require-
ments and is at least as safe as, and possibly superior to,
a more liberal approach for critically ill adults. These
data showing that restrictive transfusion triggers can
reduce red cell transfusion use without significantly
increasing adverse clinical outcomes have been repli-
cated in pediatric [6] and neonatal ICU [7] patients.
Additionally, in a recent systematic review of 45 obser-
vational trials, red cell transfusions were associated with
an increased risk of infection, multi-organ failure, and
death [8].
With regards to the HSCT population, Xenocostas et
al [2] reported that patients undergoing allogeneic trans-
plantation required an average of 6.8 ± 6.4 units of red
cells between 0 - 60 days after transplant and the fre-
quency of red cell transfusion decreased significantly
thereafter. Increased numbers of red cell transfusions
were associated with the before-transplant hemoglobin
level, major ABO mismatch between donor and recipi-
ent, transplantation in patients with more advanced dis-
ease, with the use of unrelated compared with related
donors, older patient age and female gender. The before
transplant hemoglobin level was also associated with
increased mortality within 6 months of transplant in
multivariate regression analysis. The association of
reduced hemoglobin prior to allogeneic HSCT with
increased red cell transfusion requirements and
increased 180-day mortality was confirmed in a multi-
centered analysis [3]. With regards to patients under-
going autologous transplantation, reduced hemoglobin
prior to HSCT was associated with increased red cell
transfusion requirements in a study recently published
by our group. Furthermore, reduced hemoglobin on the
day of stem cell collection was associated with lower
levels of vascular progenitor cells in the stem cell collec-
tion and increased organ-specific toxicity following
high-dose chemotherapy [4].
Conceptually, higher hemoglobin levels would corre-
late with better performance status and/or quality of
life. Indeed, there have been positive associations noted
between a higher hemoglobin and quality of life in a
variety of clinical populations [9-13]. Nonetheless, there
is a paucity of data in the transplant literature reviewing
the impact of hemoglobin levels and quality of life.
However, a reduced hemoglobin level prior to transplan-
tation has been associated with increased post transplant
mortality and toxicity [2]. It remains unclear whether
improvements in hemoglobin levels prior and/or during
transplant would abrogate these negative outcomes. The
role of red cell transfusion on the clinical outcomes
observed in patients undergoing HSCT remains poorly
understood and a prospective randomized study of
transfusion is required to gain insight and knowledge on
best transfusion practices in this high risk population.
In preparation for our trial, all adult transplant centres
associated with the Canadian Blood and Marrow Trans-
plant Group (n = 15) were asked to respond to a survey
regarding transfusion thresholds for red cells. Fourteen
centres routinely transfuse 2 units of Packed Red Blood
Cells (PRBC) when the hemoglobin < 80 g/L and/or in
response to patient specific indications. One centre
transfuses PRBCs when the hemoglobin < 70 g/L and/or
response to specific circumstances. Importantly, the
rationale for the near universal adoption of red cell
transfusion trigger of 80 g/L (personal communication
with Canadian transplant Directors) remains unclear.
There appears to be a reluctance to fully embrace a
hemoglobin trigger of 70 g/L as suggested by the
TRICC study, recognizing that there are differences
between ICU and HSCT patients. This may have lead to
a “middle of the road” approach, with centres selecting
at r i g g e ro f8 0g / Lw i t hh i s t o r i c a lr e dc e l lt r a n s f u s i o n
triggers as high as 100 g/L.
Our coordinating centre has historically adopted a red
cell transfusion trigger of 80 g/L and we recently con-
ducted an audit of our transfusion practices for the year
2009. Despite our established trigger of 80 g/L, red cell
transfusions above this trigger occurred in 50% of all
transplant patients ever requiring red cells within the 1
st
100 days of the transplant. Further, 20% of all red cell
transfusion episodes occurred above the stated trigger.
This phenomenon has also been observed in other
Canadian centres (personal communication).
No centre has clearly embraced a liberal transfusion
strategy and only 1 centre has embarked on a more
restrictive strategy. This indicates some relative
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PRBC transfusion in the HSCT population. If we assume
that the current threshold may be associated with some
potential for harm and some potential for benefit, it is
reasonable to consider whether transfusion at 70 g/L is
better or worse than transfusing at 90 g/L.
This report describes our design and methods of
TRIST, an open labeled multi-center pilot randomized
controlled trial in adult patients undergoing HSCT to
assess if restrictive strategy to maintain a hemoglobin
greater than 70 g/L compared to a more liberal strategy
of maintaining hemoglobin greater than 90 g/L is safe
and associated with reduced transplant-related mortality
following HSCT. This trial will focus on feasibility out-
comes in order to facilitate the planning and conduct of
a definitive phase III trial.
2. Methods
2.1 Trial Overview
TRIST is an open-labeled multi-center pilot parallel-arm
randomized controlled trial, where participants will be
stratified by centre (3 centres) and type of HSCT (either
autologous or allogeneic). We will recruit patients over a
2 year period and follow each participant for a minimum
of 100 days. Following a screening visit to confirm elig-
ibility, patients will be randomized with subsequent study
assessments to occur in concert with routine transplant
care on Days +7, +14, +28, +60, +100 (where Day 0 is
defined as the 1
st day of stem cell infusion). TRIST has
been funded by a peer reviewed grant by the Canadian
Blood Services (R & D Intramural Grants Competition
2010) and registered on the National Institute of Health,
Clinicaltrials.gov registry (NCT01237639).
2.2 Study participants
Study participants will be recruited from 3 Canadian
adult HSCT centers. They will be adult recipients of
either an autologous or allogeneic HSCT. We chose to
study both populations to 1) better appreciate the
potential benefits and/or harms with our intervention in
these 2 different types of HSCT and 2) to help define a
feasible primary endpoint for a definitive clinical trial.
Specific inclusion and exclusion criteria are listed in
Table 1.
2.3 Allocated treatment strategies
Eligible participants will have daily (morning) laboratory
investigations, including a Complete Blood Count (CBC)
performed as standard of care. The recipient will be ran-
domized to one of two red cell transfusion strategies, to
be carried out based on daily morning CBCs (The trans-
fusion strategy will be carried out from Day 0 until Day
100 post stem cell infusion/transplant):
1. Liberal Strategy (Red cell transfusion trigger of 90
g/L): Participants will receive 2 units of packed red
blood cells if the Hemoglobin (Hb) level is < 90 g/L,
based the day’s CBC to target a Hb level of 90-110 g/L
2. Restrictive Red cell Transfusion Strategy (Red cell
transfusion trigger of 70 g/L): Participants will receive 2
units of packed red blood cells if the Hb level is < 70 g/
L, based on the day’s CBC to target a Hb level of 70-90
g/L
Transfusion(s) of red cells outside the red cell transfu-
sion strategy is permitted when clinically indicated by
the treating physician.
2.4 Randomization and treatment allocation
The randomization process will consist of a computer
generated random list of permutated blocks of 2 and 4,
stratified by type of HSCT (autologous or allogeneic)
and by centre (3 centres). The randomization sequence
will be determined by the Ottawa Hospital Research
Institute-Methods Centre statistician, independent from
the study. After screening the patient for eligibility and
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria
1 Males or females aged 18 years or older who are undergoing either an autologous or allogeneic HSCT.
2 The indications for HSCT may include, but not limited to the following diseases:
a. Acute Leukemia, myeloid, lymphoid or biphenotypic in 1
st,2
nd remission or in relapse
b. Chronic Myeloid Leukemia in chronic, accelerated or blast phase
c. Chronic Lymphocytic Leukemia
d. Myelodysplastic Syndrome
e. Myeloproliferative Disorder
f. Lymphoma
g. Myeloma
3 All study patients must provide consent at least 1 day prior to scheduled HSCT and provide written informed consent.
Exclusion Criteria
1 Pregnant or lactating at the time of enrollment.
2 Already received red cell transfusion after conditioning chemotherapy for HSCT but prior to enrollment.
3 Unable/unwilling to providing informed consent.
4 Geographically inaccessible
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mize the patient using the number in the next chronolo-
gical order from the randomization lists provided ahead
of time by the Methods Centre. This randomization list
is secured within a password protected SQL server. The
participant’s assignment is only known once all the
inclusion criteria are reviewed and “checked-off” online.
The local research coordinator/nurse will then identify
the transfusion intervention assignment of the partici-
pant to the HSCT team.
2.5 Medical Management
In addition to the primary intervention of assignment of
either a restrictive or liberal transfusion strategy, all other
HSCT support care will be according to local institu-
tional practice. This will include, but not limited to the
use of antibiotics, analgesia,i n t r a v e n o u sf l u i d s ,g r o w t h
factors and blood products (not including red cells).
2.6 Withdrawal from study
Participants may withdraw from the study at any time and
for any reason, or maybe withdrawn at the treating physi-
cian’s discretion in the event of intolerance to transfusion
assignment, adverse events, or administrative reasons.
2.7 Study Outcome measures: Feasibility
The primary goal of this pilot study is to demonstrate
feasibility. We will (1) identify logistical issues related to
protocol implementation. Further, we will evaluate feasi-
bility of (2) recruitment rates, (3) randomization imple-
mentation strategy, (4) data collection of clinical
outcomes and (5) define the sample size required for a
definitive trial. To evaluate the feasibility of recruitment,
we will seek to demonstrate the ability to recruit 3
patients per centre per month (based on investigator
consensus).
We also seek to document compliance with the
assigned red cell transfusion threshold. Compliance will
be assessed by the number of protocol violations for red
cell transfusions (participants receiving PRBCs above or
below the assigned transfusion trigger in the absence of
a clinical rationale e.g. angina). We have arbitrarily
defined compliance (based on total PRBC transfusion
episodes) to the assigned red cell transfusion threshold
as follows: Excellent (≤5% violations), Acceptable
(between 5% and 20% violations), Poor (≥20% viola-
tions). Further, the mean difference of pre-transfusion
Hemoglobin will be calculated, in order to assess adher-
ence to the protocol.
2.8 Study Outcome measures: Clinical Outcomes
The following clinical outcomes (see Table 2 for defini-
tions) will be evaluated: 1) Transfusion Requirements
(red cells, platelets and plasma), 2) Transplant Related
Mortality, 3) Maximum grade of acute Graft versus
Host Disease [14] 4) Veno-occlusive Disease [15], 5)
Serious Infections [16], 6) Bearman Toxicity Score [17],
7) Bleeding [18], 8) Quality of Life [19,20], 9) Number
of Hospitalizations and 10) Number of ICU Admissions.
Further, we will document any transfusion reactions and
the duration of storage of each red cell unit prior to
infusion.
2.9 Blinding
This is an open labeled study. It will be impossible to
blind the assigned red cell transfusion trigger to partici-
pants and bedside caregivers since the standard of care
requires daily knowledge of hemoglobin concentration
as part of the participants’ overall HSCT care and safety.
There will be no specific measures to blind research
coordinators and study statisticians, as the clinical out-
comes sought as listed in Section 2.8 are “hard” clinical
outcomes and assigned primarily by the bedside care-
giver. Consequently, the risk of measurement bias is
minimal.
2.10 Screening, Baseline and Follow-up assessments
Potential participants will be identified by screening at
HSCT transplant consultation and/or planning visits.
Following written informed consent, demographic infor-
mation will be collected and participants will be
screened for eligibility at the screening visit (see Table 3
for study schedule and procedures at all study visits).
2.11 Sample Size
This is a pilot study that would inform a definitive trial.
The transplant related mortality (TRM) at 100 days
(main clinical outcome) is not clearly known for the
proposed red cell transfusion triggers/thresholds. We
p r o p o s eas a m p l es i z eo f5 0a d u l t si ne a c ht r e a t m e n t
group for a total sample size of 100, while stratifying for
participants undergoing either an Autologous or Allo-
geneic HSCT. Preliminary sample size calculations
based on the following assumptions, TRM of 15% in the
liberal strategy, 10% in the restrictive strategy, a =0 . 0 5
w i t hat o t a ls a m p l es i z eo f1 0 0w o u l dy i e l dap o w e ro f
7.3%. Nonetheless, the conduct of this pilot trial will
allow us to accurately estimate the event rates in all the
studied clinical outcomes and suggest feasible clinical
outcomes to evaluate.
2.12 Data Management
Data Collection is facilitated by paper-based case report
forms designed in consultation with Ottawa Hospital
Research Institute- Methods Centre. Research Coordina-
tors at each site will complete the case report forms,
check them for accuracy and completeness by reviewing
source documents and by regular interaction with the
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fax the case report forms to the coordinating centre
(Ottawa) via a dedicated fax machine. Case report forms
will be faxed to the Project Management Office at regis-
tration and at follow-up time points. Data will be identi-
fied by an alphanumeric code only. Data will be entered
into a Microsoft Access Database (within a secured SQL
server) which exactly reflects the case report forms. Any
queries arising from missing data or data anomalies will
be resolved.
Source documentation will remain at their respective
participating centre’s site. The server for the database will
be located in the Ottawa Hospital Research Institute
under the care of the Methods Centre. Appropriate secur-
ity measures will be in place such that current Canadian
privacy laws are adhered to with respect to security and
confidentiality of data, electronic data transmission, data
storage and data access. A secure ID and password will be
necessary to access the system. Audit trails of entries will
be provided. The Project Manager and delegate will be the
only individuals that can edit data.
2.13 Ethical considerations
This study will be conducted in accordance with the
Health Canada’s Good Clinical Practice (GCP) guide-
lines [21], in accordance with the current Declaration of
Helsinki and the Tri-Council Policy Statement: Ethical
Conduct for Research Involving Humans (TCPS)[22].
The study protocol and amendments and informed con-
sent forms have been approved by the research ethics
board of each participating center. Written informed
consent will be obtained from each participant.
2.14 Study Management
The principal investigator (PI) at each site will oversee
the day-to-day management of the trial, resolving ques-
tions about eligibility, enrolment, randomization, grading
and disposition of toxicities and adverse events, and
determination of outcomes questions that need resolu-
tion. Further, the trial multi-centre coordinator will pro-
vide each centre with initiation visits and at least one
monitoring visit to facilitate recruitment and ensure
data integrity.
Table 2 Definitions and Description of Clinical Outcomes
Transfusion Requirements This defined as the number of transfusions received by the recipient between the 1
st day of Stem cell
reinfusion (Day 0) and Day 100 post Hematopoietic Stem Cell Transplantation.
Transplant Related Mortality This is defined as the incidence of death from any cause at 100 days post Hematopoietic Stem Cell
Transplantation.
Maximum grade of acute Graft versus
Host Disease (GVHD)
The incidence of acute GVHD up to Day 100 will be compared. Acute GVHD will be graded according
to the Przepiorka Criteria [14].
Serious Infection Clinically important infections will be ascertained using Centre for Disease Control criteria [16].
Infections will include: serious infections such as nosocomial pneumonia; deep tissue infections
(peritonitis, mediastinitis) and bacteremia from organisms not considered normal skin flora, and judged
important enough to treat by the attending team. All grade 4 and 5 infections (according to the
Common Terminology for Adverse Events v.4) will be recorded in the Data Collection Forms. In
addition, the following information will also be recorded in the Data Collection Forms: Type of
organism (bacterial, viral, fungal or protozoal) (suspected or documented).
Bearman Toxicity Score This is a validated scoring system [17] to assess toxicity during HSCT. In this system, grade I toxicity is
reversible without treatment and grade 2 is not life threatening, but requires treatment. Grade 3
requires life-support intervention and grade 4 is fatal. Regimen-related toxicity in each organ system
was scored as the highest grade achieved in that organ system through day 28, except that deaths
occurring after day 28 as a result of regimen-related toxicity occurring before day 28 are also scored as
grade 4. Adverse events that could be attributed to infection (culture-documented), bleeding or other
medications are not scored as regimen-related toxicity. The maximum toxicity is the highest grade
recorded in any individual
organ system and the cumulative toxicity score is the sum of the highest grades recorded for all
eightorgan systems.
Veno-Occlusive Disease Diagnosis requires 2 of 3 criteria, occurring within 20 days of transplantation: 1) Bilirubin > 34.2 μmol/L
(2 mg/dL), 2) Hepatomegaly or RUQ pain of liver origin and 3) > 2% weight gain due to fluid
accumulation [15].
Bleeding The WHO Scale [18] is a credible, standardized and validated scale to assess bleeding. Grade 3 and 4
bleeding will be recorded in the data collection forms.
Quality of Life Both the FACT-BMT [20] and EQ-5D [19] scales will be used to document quality of life.
The FACT consists of 5 subscales that measure physical well-being, functional well-being, social/family
well-being and emotional well-being. The BMT subscale of the FACT includes additional items
specifically designed to test quality of life and symptoms specific to BMT patients. EQ-5D is a
standardized measure of health status developed by the EuroQol Group in order to provide a simple,
generic measure of health for clinical and economic appraisal.
HSCT: Hematopoietic Stem Cell Transplantation
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The DSMB will be independent and composed of 3
members: an expert in HSCT, an expert in transfusion
medicine, and an expert in clinical trials (chair). A
DSMB charter will be provided to the DSMB. All ser-
ious adverse events will be reported to and reviewed by
the DSMB. A DSMB meeting will be conducted once 25
patients have completed their treatment phase of the
study. Subsequently, the DSMB will meet after every
25
th participant is randomized and reports to the co-
PIs. Should safety issues arise that the DSMB feel com-
promises the trial and/or participant safety, then a meet-
ing will be convened of all co-investigators to consider
amending or stopping the trial. DSMB will receive three
interim reports and can, at any time, recommend termi-
nation of the study in the event that it appears unsafe to
continue. There is no stopping rules for this pilot study;
the steering committee and DSMB will use their judg-
ment in the event the trial has to be terminated early
for safety concerns.
All interim reports (summarized by the study statisti-
cian) will include the following aggregated data: 1)
Number of patients enrolled, 2) Proportion of patients
at 28 days, 3) Proportion of patients at 100 days, 4)
Number of autologous and allogeneic HSCTs, 5) Num-
ber of Red cell Transfusions, 6) Mean difference of pre-
transfusion Hemoglobin (to assess adherence to the pro-
tocol), 7) Transfusion Reactions from Red cells, 8)
Bleeding as per WHO scale, 9) Veno-occlusive Disease
for recipients of Allogeneic HSCT, 10) Assessment of
the Bearman Toxicity Score, 11) Acute GVHD for reci-
pients of Allogeneic HSCT, 12) Number of
Table 3 Schedule and Evaluation of Outcomes
Study Entry Scheduled Assessments
(± 3 days as inpatient; ± 5 days as outpatient)
Day 0 Day 7 Day 14 Day 28 Day 60 Day 100
Demographics/Baseline characteristics Trial Case Number x
Date of Birth x
Gender x
Indication for HSCT x
Stem cell Source x
CD34 cell count x
Donor Type (allos only) x
HLA compatibility (allos only) x
ABO blood type x
ABO compatibility (allos only) x
CMV compatibility (allos only) x
Karnofsky Functional Scale x
Conditioning regimen x
HCT-CI x
CBC x all available values
Quality of Life Scales EQ-5D and FACT-BMT† x x xxx x
Transfusion Assessments Red Cells Transfusion Assessment As needed
Platelets Transfusion Assessment As needed
Plasma and Cryoprecipitate Transfusion Assessment As needed
Transplant Assessments Bleeding Assessment x x x
Infection Assessment x x x
VOD Assessment
# x
Bearman Toxicity Assessment^ x
aGVHD* x
Admission to ICU As needed
Hospital Admission As needed
Mortality Assessment x
NB Scheduled Assessments will be required even if the patient is discharged; the assumption is that no transplant toxicities have occurred if the patient is
discharged
† Quality of Life Scales may be completed at home to be mailed or handed in
# Presence/Absence within the 1st 21 days of HSCT (by Seattle Criteria) ^ Highest grade to be completed * Highest grade of aGVHD to be completed
HLA: Human Leukocyte Antigen; CMV: Cytomegalovirus; HCT-CI: Hematopoietic Cell Transplantation-Comorbidity Index; CBC: Complete Blood Count;
VOD: Veno-occlusive Disease; aGVHD: acute graft versus host disease; ICU: Intensive Care Unit
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start of conditioning up until 100 days or death, which-
ever occurs first, 13) Number of ICU Admissions (and
length of each admission) from start of conditioning up
until 100 days or death, whichever occurs first, 14) Ser-
ious Adverse Events, 15) Grade 4 and 5 Infections and
16) Deaths. Further data will be provided to the DSMB
when deemed necessary by the DSMB.
The board comprises of Dr. Donald Arnold (Chair),
Program Director, Transfusion Medicine McMaster Uni-
versity, Dr. Stephan Couban, HSCT Physician at Dal-
housie University and Dr. Lois Shepard, Transfusion
Medicine Physician at Queens University.
2.16 Statistical Analysis
The number of eligible participants will be documented
and the proportion of randomized patients noted
monthly. Recruitment at each participating centre will
be summarized by the number of randomized partici-
pants on a monthly basis. Feasibility of data collection
will be assessed by the number of missing or erroneous
data at each centre and summarized by proportions.
Clinical outcomes will be collected as described above;
they will be compared between the 2 groups (liberal and
restrictive red cell transfusion strategy). These will
include transfusion requirements (number of PRBC
units, platelets and plasma), transplant related mortality
at 100 days (yes/no), maximum grade of acute graft ver-
sus host disease, incidence of acute graft versus host dis-
ease at 100 days, veno-occlusive disease, incidence of
grade 4 and 5 infections at 100 days, Bearman toxicity
scores, incidence of bleeding, incidence of hospital
admissions, incidence of ICU admissions and quality of
life.
Comparisons of time to failure endpoints will incorpo-
rate Kaplan-Meier probability estimates, log rank testing
and, when adjustment of covariates is made, use of the
Cox proportional hazards model. Binary/categorical end-
points will be compared between treatment groups
using logistic regression. The effect of missing data and
outliers will be subjected to sensitivity analysis. The
results for each of endpoints will be summarized by a
significance test and 95 per cent confidence interval.
Analysis of secondary endpoints will be considered
exploratory and hypothesis generating. Given that multi-
p l ec o m p a r i s o n si n c r e a s et h ep r o b a b i l i t yo faT y p eI
error, adjustment of individual statistical tests using a
more strict cut point (p < 0.01) will be used to facilitate
interpretation. All statistical tests quoted will be 2-tailed.
Analysis will follow the intention-to-treat principle.
Analyses will be conducted using SAS version 9.2 and/
or SPSS.
Sub-group analysis will be conducted as follows: The
two treatment groups will be compared among
recipients of allogeneic or autologous Hematopoietic
Stem cell Transplantation. Results will be considered
hypothesis-generating.
3. Conclusions
The role of red cell transfusion on the clinical outcomes
observed in patients undergoing HSCT remains poorly
understood and a prospective randomized study of
transfusion is required to gain insight and knowledge on
best transfusion practices in this high risk population.
While there are clear benefits of red cell transfusion,
potential harm has been described in several patient
groups. Given the resource utilization and high rate of
adverse outcomes in HSCT, our study will provide the
framework for better understanding the optimal use of
red cell transfusion in this important group of high risk
cancer patients. In this study, we aim to determine the
feasibility and logistics of conducting a multicenter trial
and determine clinical outcome rates in order to plan
and execute a prospective definitive randomized study
to evaluate the impact of a restrictive and liberal red cell
transfusion threshold on transplant outcomes.
4. Milestones and current status
This trial was conceived and designed in 2009. Peer
reviewed funding through the Canadian Blood Services
(Health Canada) intramural grant was sought in 2010,
and successfully obtained in 2010. The study began
enrolling in March, 2011. Two of 5 invited Canadian
Transplant Centres declined participation due to logisti-
cal reasons. One center (Saskatoon) is currently in the
local ethics approval process and the other (London)
has recently enrolled 1 patient. The primary centre
(Ottawa) has enrolled 20 patients as of 15 July 2011.
Enrollment is reaching its quarter and the DSMB will be
reviewing our progress shortly.
5. Abbreviations
HSCT: Hematopoietic Stem cell Transplantation; ICU:
Intensive Care Unit; PRBC: Packed Red Blood Cells;
CBC: Complete Blood Count; TRM: Transplant Related
Mortality; DSMB: Data Safety Monitoring Board.
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